Medicals ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  0.7% 0.7% 0.7% 0.7% 0.7%  
Bankruptcy risk  0.0% 8.7% 5.2% 6.9% 3.5%  
Credit score (0-100)  0 27 42 34 53  
Credit rating  N/A BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 632 0 0 0  
Gross profit  0.0 451 1,093 5,712 3,693  
EBITDA  0.0 442 736 3,797 1,145  
EBIT  0.0 442 736 3,797 1,145  
Pre-tax profit (PTP)  0.0 441.5 732.2 3,810.4 1,088.1  
Net earnings  0.0 342.4 571.9 2,968.5 846.6  
Pre-tax profit without non-rec. items  0.0 442 732 3,810 1,088  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 382 954 3,805 887  
Interest-bearing liabilities  0.0 33.6 0.0 0.0 525  
Balance sheet total (assets)  0.0 515 1,229 35,471 3,279  

Net Debt  0.0 -436 -1,047 -24,678 -2,145  
 
See the entire balance sheet

Volume 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 632 0 0 0  
Net sales growth  0.0% 0.0% -100.0% 0.0% 0.0%  
Gross profit  0.0 451 1,093 5,712 3,693  
Gross profit growth  0.0% 0.0% 142.6% 422.5% -35.3%  
Employees  0 1 0 2 3  
Employee growth %  0.0% 0.0% -100.0% 0.0% 50.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 515 1,229 35,471 3,279  
Balance sheet change%  0.0% 0.0% 138.6% 2,785.8% -90.8%  
Added value  0.0 442.0 736.5 3,797.3 1,145.0  
Added value %  0.0% 69.9% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 -1.0 0.0 0.0  
EBIT trend  0.0 1.0 2.0 3.0 4.0  

Profitability 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 69.9% 0.0% 0.0% 0.0%  
EBIT %  0.0% 69.9% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 98.1% 67.4% 66.5% 31.0%  
Net Earnings %  0.0% 54.2% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 54.2% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 69.9% 0.0% 0.0% 0.0%  
ROA %  0.0% 85.9% 84.4% 20.8% 6.2%  
ROI %  0.0% 106.3% 107.5% 160.4% 46.2%  
ROE %  0.0% 89.5% 85.6% 124.7% 36.1%  

Solidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 74.2% 77.6% 10.7% 27.0%  
Relative indebtedness %  0.0% 21.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% -53.3% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -98.7% -142.1% -649.9% -187.3%  
Gearing %  0.0% 8.8% 0.0% 0.0% 59.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 4.6% 25.3% 0.0% 44.7%  

Liquidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 3.7 4.4 1.1 1.4  
Current Ratio  0.0 3.7 4.4 1.1 1.4  
Cash and cash equivalent  0.0 469.7 1,046.6 24,678.0 2,669.8  

Capital use efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 77.2% 0.0% 0.0% 0.0%  
Net working capital  0.0 355.4 927.4 3,778.1 859.7  
Net working capital %  0.0% 56.2% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 632 0 0 0  
Added value / employee  0 442 0 1,899 382  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 442 0 1,899 382  
EBIT / employee  0 442 0 1,899 382  
Net earnings / employee  0 342 0 1,484 282